Medpace Holdings Inc. (NASDAQ: MEDP) experienced a significant surge of 15.54% in after-hours trading, driven by the release of its second-quarter financial results for fiscal year 2026 that substantially exceeded analyst expectations.

The clinical research organization reported Q2 earnings per share of $4.25, beating the consensus estimate of $3.97 by 7.05% and representing a 37.1% increase from the same period last year. Quarterly revenue reached $707.331 million, surpassing the estimated $687.647 million by 2.86% and climbing 17.2% year-over-year. Additionally, the company demonstrated strong operational performance with net new business awards jumping 28.2% to $795.7 million.

Further bolstering investor sentiment, Medpace provided optimistic full-year guidance, forecasting revenue between $2.81 billion and $2.89 billion and earnings per share of $17.25 to $17.95 for 2026, both ranges above consensus analyst estimates.